ESMO 2019: 5-year Update of Checkmate 067

ESMO 2019: 5-year Update of Checkmate 067

Publication date: Oct 25, 2019

Associate Professor Victoria Atkinson summarises the update on the

CheckMate 067 – nivolumab plus ipilimumab in unresectable stage III-IV melanoma trial presented at ESMO Barcelona 2019.

Faculty:

Associate Professor Victoria Atkinson

Senior Medical Oncologist,

Princess Alexandra Hospital, Brisbane, QLD

—–

Website: www.MDBriefCase.com

Facebook: https://www.facebook.com/mdbriefcase

Twitter: https://twitter.com/mdbriefcase

Instagram: https://www.instagram.com/mdbriefcase/

LinkedIn: https://www.linkedin.com/company/mdbriefcase/

Concepts Keywords
Abalone IV melanoma
Albany Surgery
Aluminum Radiation
Australia RTT
Autoimmune Cancer
Balloon Bristol-Myers Squibb
Barcelona Ipilimumab
Beer Melanoma
Brisbane Radiation therapy
Checkmate Medicine
Comb Branches of biology
Combination Therapy Health
Ebola Radiation
Fraud
Hepatitis
Hyperthyroidism
Incidence
Instagram
Ipilimumab
Italy
LinkedIn
Mab
Mabon
Mayo
Median Nerve
Medicine
Melanoma
Morbidity
Mutant
Mutation
Nipple
Niva
Oncologist
Qalat
Radiation
Subgroup
Systemic Therapy
Targeted Therapy
Toxicity
Victoria
Wild Type

Semantics

Type Source Name
drug DRUGBANK Nivolumab
drug DRUGBANK Ipilimumab
disease MESH melanoma
disease DOID melanoma
pathway BSID Melanoma
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *